Published in Cancer Res on November 01, 1993
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 1.03
Update on toll-like receptor-directed therapies for human disease. Ann Rheum Dis (2007) 1.00
Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother (2003) 0.97
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol (2011) 0.88
Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization. PLoS One (2011) 0.84
Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets? Front Cell Infect Microbiol (2014) 0.84
Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity. J Immunol (2015) 0.82
Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob Agents Chemother (2009) 0.77
Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med (2007) 0.76
The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. J Invest Dermatol (2016) 0.75
Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS One (2017) 0.75
A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. Anal Biochem (1977) 14.08
Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA (1998) 12.60
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials (2000) 5.37
Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol (2000) 4.73
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Outcomes of a randomized community-level HIV prevention intervention for women living in 18 low-income housing developments. Am J Public Health (2000) 3.41
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
Subsequent pulmonary embolism: risk after a negative helical CT pulmonary angiogram--prospective comparison with scintigraphy. Radiology (2000) 3.06
A unique set of polypeptides is induced by gamma interferon in addition to those induced in common with alpha and beta interferons. Nature (1983) 2.68
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Bridging the gap between the science and service of HIV prevention: transferring effective research-based HIV prevention interventions to community AIDS service providers. Am J Public Health (2000) 2.31
Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol (1997) 2.21
The value of the forced expiratory time in the physical diagnosis of obstructive airways disease. JAMA (1993) 2.18
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics (2001) 2.10
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Variability in 28-day outcomes for very low birth weight infants: an analysis of 11 neonatal intensive care units. Pediatrics (1988) 1.99
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention. Psychiatr Serv (1997) 1.75
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Surrogates' predictions of seriously ill patients' resuscitation preferences. Arch Fam Med (1995) 1.70
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Underutilization of mammography in older breast cancer survivors. Med Care (2000) 1.66
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Programmes, resources, and needs of HIV-prevention nongovernmental organizations (NGOs) in Africa, Central/Eastern Europe and Central Asia, Latin America and the Caribbean. AIDS Care (2006) 1.58
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet (1992) 1.52
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood (1992) 1.46
Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler (2007) 1.45
Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med (1991) 1.43
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. J Infect Dis (1970) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. J Neurosurg (1993) 1.40
Tracheal advancement flap for postlaryngectomy stomal stenosis. Head Neck (1997) 1.39
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
Is shorter always better? Relative importance of questionnaire length and cognitive ease on response rates and data quality for two dietary questionnaires. Am J Epidemiol (2001) 1.35
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
The neuraminidase yield-reduction bioassay of human other interferons. Proc Soc Exp Biol Med (1975) 1.29
Identifying, recruiting, and assessing social networks at high risk for HIV/AIDS: methodology, practice, and a case study in St Petersburg, Russia. AIDS Care (2005) 1.28
Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care (1995) 1.27
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
Predictors of HIV risk behavior among Russian men who have sex with men: an emerging epidemic. AIDS (2001) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
HIV risk characteristics and prevention needs in a community sample of bisexual men in St. Petersburg, Russia. AIDS Care (2002) 1.17
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14
The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol (1998) 1.14
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
The effect of host age, virus dose and route of inoculation on inapparent infection in mice with Japanese encephalitis virus. Proc Soc Exp Biol Med (1966) 1.13
Comparison of 10% povidone-iodine and 0.5% chlorhexidine gluconate for the prevention of peripheral intravenous catheter colonization in neonates: a prospective trial. Pediatr Infect Dis J (1995) 1.11
Peer discussions of cancer among Hispanic migrant farm workers. Public Health Rep (1994) 1.11
Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med (1986) 1.11
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
HIV risk behavior and risk-related characteristics of young Russian men who exchange sex for money or valuables from other men. AIDS Educ Prev (2001) 1.09
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer (1990) 1.07
Current HIV prevention activities for women and gay men among 77 ASOs. J Public Health Manag Pract (1999) 1.07
Factors influencing attitudes within AIDS service organizations toward the use of research-based HIV prevention interventions. AIDS Educ Prev (1999) 1.07
Functional MR activation correlated with intraoperative cortical mapping. AJNR Am J Neuroradiol (1997) 1.07
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06
Transmissible retrovirus in Epstein-Barr virus-producer B95-8 cells. Virology (1995) 1.06
Evaluation of fetal growth by estimation of neonatal body composition. Obstet Gynecol (1992) 1.06
Hyperlipaemia following viral infection in the chicken embryo: a new syndrome. Nature (1965) 1.05
A sensitive interferon assay for many species of cells: encephalomyocarditis virus hemagglutinin yield reduction. Proc Soc Exp Biol Med (1977) 1.05
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05
A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics (1999) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res (1998) 1.04
A comparison of functional MR activation patterns during silent and audible language tasks. AJNR Am J Neuroradiol (1995) 1.04
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Repression of interferon action: induced dedifferentiation of embryonic cells. Science (1971) 1.03
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
The interferons and their inducers: molecular and therapeutic considerations. 3. N Engl J Med (1972) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother (1978) 1.01
The interferons and their inducers: molecular and therapeutic considerations. 1. N Engl J Med (1972) 1.01
Clostridial septicemia complicating the course of leukemia. Cancer (1986) 1.00
Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol (1991) 1.00